Squarepoint Ops LLC Increases Position in Kymera Therapeutics, Inc. $KYMR

Squarepoint Ops LLC lifted its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 657.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 97,189 shares of the company’s stock after purchasing an additional 84,350 shares during the period. Squarepoint Ops LLC’s holdings in Kymera Therapeutics were worth $11,145,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its position in Kymera Therapeutics by 10,989.5% during the second quarter. California State Teachers Retirement System now owns 6,241,373 shares of the company’s stock worth $715,698,000 after buying an additional 6,185,091 shares during the period. BlackRock Inc. acquired a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at approximately $635,067,000. Baker BROS. Advisors LP boosted its stake in shares of Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after acquiring an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after acquiring an additional 1,124,747 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after acquiring an additional 1,061,957 shares during the period.

Kymera Therapeutics Stock Performance

KYMR stock opened at $115.43 on Thursday. The stock’s 50 day moving average price is $114.38 and its 200 day moving average price is $95.64. The firm has a market cap of $9.60 billion, a P/E ratio of -35.63 and a beta of 1.96. Kymera Therapeutics, Inc. has a 1 year low of $42.71 and a 1 year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. During the same quarter last year, the business posted ($0.95) earnings per share. Kymera Therapeutics’s revenue was up 465.2% compared to the same quarter last year. On average, research analysts predict that Kymera Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on KYMR shares. Citigroup reaffirmed a “buy” rating on shares of Kymera Therapeutics in a report on Thursday, August 6th. Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Bank of America raised their price target on Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Guggenheim lifted their price target on Kymera Therapeutics from $135.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, August 31st. Finally, BTIG Research reiterated a “buy” rating and issued a $134.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $128.70.

Insider Buying and Selling at Kymera Therapeutics

In related news, CFO Bruce Jacobs sold 77,109 shares of Kymera Therapeutics stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the completion of the sale, the chief financial officer owned 244,883 shares in the company, valued at approximately $28,151,749.68. This trade represents a 23.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Nello Mainolfi sold 50,000 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $79,321,592. The trade was a 6.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,594,000 shares of company stock valued at $386,928,106. 15.98% of the stock is owned by company insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.